Supplementary Figure 3

A SDS-PAGE/Electropherogram



B Octet



C



D MDA-MB-231 Trial 1



E MDA-MB-231 Trial 2



Fig S3. Anti-EMP2 mAbs reduce tumor load in two trials using MDA-MB-231 xenograft models. A. Analysis of the anti-EMP2 mAb. SDS-PAGE and an electropherogram were used to confirm the integrity of both the reduced and unreduced mAb. B. Affinity of the anti-EMP2 mAb was confirmed against a biotinylated EMP2 peptide using the Octet system. This work was completed under contract by Lake Pharma. C. The triple negative primary tumorgraft HCI-002 was implanted into the mammary fat pad of NOD-SCID animals. Following treatment with either control mAbs or an anti-EMP2 mAb, tumors were harvested, fixed, and stained for ALDH1 or EMP2 expression using standard immunohistochemistry. Representative images are shown. Magnification=200X. D, E. MDA-MB-231 tumors were implanted into Balb/c Nude mice. Tumors were treated with control or anti-EMP2 mAbs in two independent trials with both grouped and individual data shown. In both trials, significant differences were observed by Two-way ANOVA, with results indicated on the respective graphs. The arrow indicates treatment initiation. Tumors from these experiments were harvested and then reimplanted into secondary animals at limiting dilutions.